Jameson Tl Berry

Jameson Tl Berry

Auto-generated profile, based on publicly available information

Jameson Tl Berry

Department of Pediatrics, Emory University, Atlanta, GA, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Oncolytic Virotherapy
Verified
Journal Article
Open access
PDF file
MPMatthew B Phillips
Matthew B Phillips
JSJohnasha D Stuart
Johnasha D Stuart
RSRoxana M Rodríguez Stewart
Roxana M Rodríguez Stewart
JBJameson Tl Berry
Jameson Tl Berry
BMBernardo Mainou
Bernardo Mainou
Karl BoehmeKarl Boehme
Karl Boehme
Mammalian orthoreovirus (reovirus) is under development as a cancer virotherapy. Clinical trials demonstrate that reovirus-based therapies are safe and tolerated in patients with a wide variety of cancers. Although reovirus monotherapy has proven largely ineffective, reovirus sensitizes cancer cells to existing chemotherapeutic agents and radiation. Clinical trials are underway to test the efficacy of reovirus in combination with chemotherapeutic and radiation regimens and to evaluate the effectiveness of reovirus in conjunction with immunotherapies. Central to the use of reovirus to treat cancer is its capacity to directly kill cancer cells and alter the cellular environment to augment other therapies. Apoptotic cell death is a prominent mechanism of reovirus cancer cell killing. However, reoviruses can also kill cancer cells through nonapoptotic mechanisms. Here, we describe mechanisms of reovirus cancer cell killing, highlight how reovirus is used in combination with existing cancer treatments, and discuss what is known as to how reovirus modulates cancer immunotherapy.